The global secondary myelofibrosis therapeutics market, valued at USD 1.4 million in 2022, is set to experience notable growth over the coming decade, projected to expand at a CAGR of 6.3% from 2023 to 2033 and reach a valuation of USD 2.74 million by the end of the forecast period. Key drivers of this growth include a rising incidence of secondary myelofibrosis, substantial investments in research and development, and the continuous emergence of novel therapeutic options. In the historical period from 2018 to 2022, the market saw a CAGR of 3.3%, reflecting an increasing demand for effective treatments.
Secondary myelofibrosis, a progressive bone marrow disorder, has gained heightened attention due to its complex nature and impact on patient health. Pharmaceutical companies and research institutions worldwide are dedicating resources to advance treatment solutions and improve patient outcomes. The anticipated growth in this market is further bolstered by ongoing clinical trials and the anticipated launch of next-generation therapies, which are expected to improve both the efficacy and accessibility of treatments for secondary myelofibrosis patients globally.
The therapeutics for Secondary Myelofibrosis may include drugs that target specific molecular pathways involved in the disease, as well as supportive therapies such as blood transfusions, bone marrow transplants, and palliative care to relieve symptoms and improve quality of life. The treatment approach for Secondary Myelofibrosis may vary depending on the individual patient’s condition and medical history.
Market Competition
Key players in the secondary myelofibrosis therapeutics market are CTI BioPharma Corp, Incyte Corporation, Bristol-Myers Squibb Company, Amneal Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Pfizer Inc., Actuate Therapeutics Inc., Imago BioSciences, Galecto, Inc.
- CTI BioPharma’s is offering pacritinib, a selective inhibitor of both JAK2 and FLT3. JAK2 inhibition is an important therapeutic target in secondary myelofibrosis, as the JAK2 mutation is commonly found in patients with this condition. Pacritinib has been evaluated in several clinical trials, including the Phase 3 PERSIST-1 and PERSIST-2 trials, which showed promising results in reducing spleen volume and improving symptoms in patients with myelofibrosis, including those with secondary myelofibrosis.
- Incyte Corporation is offering ruxolitinib, a JAK1/JAK2 inhibitor that was approved by the US Food and Drug Administration (FDA) for the treatment of intermediate or high-risk primary myelofibrosis, as well as post-PV and post-ET myelofibrosis. Ruxolitinib has been evaluated in several clinical trials for secondary myelofibrosis, including the Phase 3 COMFORT-I and COMFORT-II trials, which showed significant reductions in spleen volume and improvements in symptoms in patients with myelofibrosis, including those with secondary myelofibrosis.
Key Companies Profiled
- CTI BioPharma Corp
- Incyte Corporation
- Bristol-Myers Squibb Company
- Amneal Pharmaceuticals, Inc.
- AbbVie Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Actuate Therapeutics Inc.
- Imago BioSciences
- Galecto, Inc.
Key Segments Profiled in the Secondary Myelofibrosis Therapeutics Industry Survey
Treatment:
- Targeted therapy
- Chemotherapy
- Radiation therapy
Diagnosis:
- Physical exam
- Blood tests
- Imaging tests
- Bone marrow examination
Drug Class:
- Ruxolitinib
- Fedratinib
- Pomalidomide
Distribution Channel:
- Hospital pharmacies
- Retail and specialty pharmacies
- Online pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube